Abstract:3039 Background: Immunotherapy targeting the PD1/PDL1 checkpoint has shown promising efficacy in patients with non-small cell lung cancer (NSCLC). LAG-3/MHC II is another important checkpoint that may have a synergistic interaction with PD-L1/PD-1. In this study, we describe the protein expression of LAG 3, MHC 2, PD 1 and PD L1 and their associations with survival in patients with NSCLC. Methods: The expression of LAG3 (EPR4392, Abcam), MHC II (DP, DQ, DR) (CR3/43, Abcam), PD 1 (NAT 105, Cell marque) and PD L1 (22C3, Dako) was evaluated in 139 surgically resected specimens from patients with NSCLC by immunohistochemistry (IHC). Results: LAG 3 was expressed on the immune cells in 49 (35.3%) patients. MHC II was expressed in 37 (26.6%) patient tumor cells. 60 samples (43.2%) stained positive for PD 1 on the immune cells, and 25 (18.0%) had positive PD L1 expression on tumor cells. There was no LAG 3 or PD 1 expression on tumor cells. LAG 3 on immune cells was overexpressed in squamous carcinoma compared to adenocarcinoma (P = 0.044). MHC II on tumor cells was expressed less in squamous carcinoma (P = 0.043) and smokers (P = 0.004) compared to adenocarcinoma and non-smokers. LAG 3 expression on immune cells was correlated with the expression of PD 1 (P＜0.001) on immune cells and PD L1 (P = 0.006) on tumor cells. Expression of PD L1 on tumor cells and PD 1 on immune cells were positively correlated (P = 0.026). Expression of PD L1 on tumor cells and on immune cells was negatively correlated (P = 0.819). PD L1 (tumor cells) negative patients had a longer disease free survival (DFS) (1.85 years [95% CI 0.41–3.28] vs. 0.97 years [0.709–1.231]; P = 0.038). DFS was longest in both PD L1 and LAG 3 negative patients（PD L1 on tumor cells and LAG 3 on immune cells）, followed by patients for only PD L1 or LAG 3 positive, and DFS was shortest in patients positive for both PD L1 and LAG 3 (2.09 years [95% CI 0.25-3.93] vs. 1.76 years [0.67-2.85] vs. 0.67 years [0.17-1.18]; P = 0.018). Cox regression analysis showed that positive LAG 3 expression on immune cells was a poor prognostic factor for NSCLC patients (P = 0.040, EXP (B) 1.964, 95%CI 1.030-3.747). Conclusions: LAG 3 expression was correlated with PD 1/PD L1 expression and was associated with poor prognosis in patients with NSCLC.

Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

PD-L1 Expression and Its Effect on Clinical Outcomes of EGFR-mutant NSCLC Patients Treated with EGFR-TKIs

Characterization of PD-L1 Protein Expression and CD8+ Tumor-Infiltrating Lymphocyte Density, and Their Associations with Clinical Outcome in Small-Cell Lung Cancer.

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Prognostic Value of PD-L1 Expression in Combination with CD8+ TILs Density in Patients with Surgically Resected Non-Small Cell Lung Cancer.

The Combination of Anti-Kir Monoclonal Antibodies with Anti-Pd-1/pd-l1 Monoclonal Antibodies Could Be a Critical Breakthrough in Overcoming Tumor Immune Escape in NSCLC

LAG 3/MHC 2 and PD 1/PD L1 Expression in Non-Small Cell Lung Cancer Patients.

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors among NSCLC Patients with EGFR Mutation.

JCES01.18 Dual Positive PD-L1 and CD8+ TIL Represents a Predominant Subtype in NSCLC and Correlates with Augmented Immunogenicity

PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort

T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer

Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients

Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma.

P3.02c-060 Dual Positive PD-L1 and CD8+ TIL Represents a Predominant Subtype in NSCLC and Correlates with Augmented Immunogenicity: Topic: IT Biomarkers

In-depth genomic characterization of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients.

Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors

PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer

Stromal PD L1–positive regulatory T cells and PD 1–positive CD8 positive T cells define the response of different subsets of non–small cell lung Cancer to PD 1/PD L1 blockade …

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation